Yiming Anke completed 70 million yuan Pre-B-plus round financing to help CD47 targeted drug clinical research and development.

On August 25th, Yiming Anke announced the completion of a 70 million yuan Pre-B-plus round of financing, which will be funded exclusively by the third phase of the Communist Youth City Regis.
focuses on the development of oncology immunotherapy, and this financing will be used primarily for clinical trials of CD47's fusion protein drug IMM01 and CD47xCD20 dual anti-IM0306.
as one of the hot targets in the field of anti-tumor immunotherapy, CD47 antibody has been the industry as the next "star" in the field of tumor immunotherapy after PD-1/PD-L1 antibody.
In a press release issued earlier by Yiming anecdote, the company has established a product pipeline covering seven new drugs based on the antibody product technology platform and the dual-target and multi-target-specific "mAb-Trap" technology platform based on Iminenko's earlier press release.
currently, Yiming Anke has two products in the research into the clinical research stage, respectively, IMM01 and IM0306.
IMM01, a fusion protein drug targeted at CD47, is conducting a Phase 1 clinical study in China on recurring or recurring lymphoma.
IMM0306 is a dual-anti-drug drug that can target both CD47 and CD20, and a Phase 1 clinical study is being conducted in China to assess the safety and resistance of single and multiple administration of injectable IMM0306 and pharmacodynamics in patients with refractic or recurring CD20-positive B-cell non-Hodgkin's lymphoma.
the 70 million yuan Pre-B-plus round of financing, will be mainly used for the above two drugs clinical trial research.
clinical trials of two projects, IMM01 and IM0306, which have natural safety advantages and do not cause significant blood toxicity, are progressing as planned, while at the same time having the effective properties of a single drug.
this round of financing will provide a strong guarantee for the company to move forward with clinical trials quickly.
.